Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005657 · ClinicalTrials.gov registry record
Genetics of Hepatitis C Virus Infection
A clinical trial of Hepatitis C and Liver Disease, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- 870
- Enrollment target
- 1
- Study location
NCT00005657: Completed study of Hepatitis C and Liver Disease, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00005657 is a study of Hepatitis C and Liver Disease that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 870 participants, below the 1,882-participant average among 106 other Hepatitis C trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005657, a study of Hepatitis C and Liver Disease, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- 870 participants
- Enrollment target
- 1
- Study location
Study Summary
The diverse clinical syndromes associated with hepatitis C underscore the multifactorial and polygenic nature of HCV infection. Both viral and host factors likely contribute to variations in infection outcome, disease susceptibility and progression, and treatment response. This protocol will focus on the immunogenetics of HCV infection. Various candidate genes, most of them related to host immune response in microbial infection, have defined genetic polymorphisms that have been associated with variable manifestations of infections including malaria, tuberculosis, leprosy, AIDS and hepatitis B. In this proposal, we plan to collect peripheral blood mononuclear cells as a source of DNA from approximately 1500 patients with HCV infection, analyze genetic polymorphisms of various candidate genes in association with viral clearance, disease progression or treatment response, and characterize the functional consequences of these polymorphisms in patients with well-defined clinical sequelae of HCV infection. We will also collect blood from patients with other forms of liver diseases (approximately 300) or normal volunteers (approximately 200) as controls. By identifying relevant host factors genetically and investigating their molecular interactions with HCV, we may gain additional insights into HCV pathogenesis and uncover new potential targets for vaccine development and treatment intervention.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 870 participants |
| Start Date | 2000-05-04 |
| Est. Completion | 2011-04-19 |
What the finished NCT00005657 record still lists
NCT00005657 is an observational study that tracks outcomes without assigning an intervention. The registered 870 participants enrollment target is mid-sized for trials with a published cap, below the 1,882-participant average among 106 other Hepatitis C trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Hepatitis C appearing as the primary indexed condition, and to 0 interventions.
NCT00005657 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00005657 about?
NCT00005657 is a clinical study titled "Genetics of Hepatitis C Virus Infection". The diverse clinical syndromes associated with hepatitis C underscore the multifactorial and polygenic nature of HCV infection. Both viral and host factors likely contribute to variations in infection outcome, disease susceptibility and progression, and treatment response. This protocol will focus o...
What is the current status of trial NCT00005657?
This trial is currently completed. The enrollment target is 870 participants. The study started on 2000-05-04. Estimated completion is 2011-04-19.
What conditions does trial NCT00005657 study?
This clinical trial studies the following conditions: Hepatitis C, Liver Disease.
Who is sponsoring clinical trial NCT00005657?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005657 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00005657's enrollment target sits among peer trials
870 9th of 106 higher than 98 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DBS TaT in Peer-assisted Telemedicine for Hepatitis C
RECRUITING · NA
-
Evaluation of Patients With Liver Disease
RECRUITING
-
The HOPE Study: Characterizing Patients With Hepatitis B and C
RECRUITING
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs
RECRUITING · NA
-
The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI